nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—ABCB1—hematologic cancer	0.0644	1	CbGaD
Fluvoxamine—CYP1A2—Anagrelide—hematologic cancer	0.0156	0.0252	CbGbCtD
Fluvoxamine—CYP1A1—Methoxsalen—hematologic cancer	0.0156	0.0252	CbGbCtD
Fluvoxamine—CYP2B6—Thiotepa—hematologic cancer	0.0153	0.0247	CbGbCtD
Fluvoxamine—CYP1A1—Bortezomib—hematologic cancer	0.0148	0.024	CbGbCtD
Fluvoxamine—CYP1A1—Daunorubicin—hematologic cancer	0.0142	0.0229	CbGbCtD
Fluvoxamine—CYP1A1—Thalidomide—hematologic cancer	0.0129	0.0209	CbGbCtD
Fluvoxamine—CYP1A1—Dacarbazine—hematologic cancer	0.0111	0.018	CbGbCtD
Fluvoxamine—CYP2E1—Thalidomide—hematologic cancer	0.00999	0.0161	CbGbCtD
Fluvoxamine—CYP2C9—Bexarotene—hematologic cancer	0.00975	0.0157	CbGbCtD
Fluvoxamine—ABCB1—Lenalidomide—hematologic cancer	0.00946	0.0153	CbGbCtD
Fluvoxamine—CYP3A7—Ifosfamide—hematologic cancer	0.00911	0.0147	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00911	0.0147	CbGbCtD
Fluvoxamine—CYP1A1—Dasatinib—hematologic cancer	0.00874	0.0141	CbGbCtD
Fluvoxamine—CYP3A7—Imatinib—hematologic cancer	0.0087	0.0141	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0087	0.0141	CbGbCtD
Fluvoxamine—CYP2B6—Ifosfamide—hematologic cancer	0.00868	0.014	CbGbCtD
Fluvoxamine—CYP2E1—Dacarbazine—hematologic cancer	0.00859	0.0139	CbGbCtD
Fluvoxamine—CYP3A5—Daunorubicin—hematologic cancer	0.00852	0.0138	CbGbCtD
Fluvoxamine—CYP2D6—Lomustine—hematologic cancer	0.00829	0.0134	CbGbCtD
Fluvoxamine—CYP1A2—Carmustine—hematologic cancer	0.0082	0.0132	CbGbCtD
Fluvoxamine—CYP2C9—Idarubicin—hematologic cancer	0.00808	0.0131	CbGbCtD
Fluvoxamine—CYP3A5—Thalidomide—hematologic cancer	0.00776	0.0125	CbGbCtD
Fluvoxamine—CYP2B6—Nilotinib—hematologic cancer	0.00753	0.0122	CbGbCtD
Fluvoxamine—CYP3A5—Teniposide—hematologic cancer	0.00741	0.012	CbGbCtD
Fluvoxamine—CYP2D6—Idarubicin—hematologic cancer	0.00739	0.0119	CbGbCtD
Fluvoxamine—CYP2C19—Bortezomib—hematologic cancer	0.00719	0.0116	CbGbCtD
Fluvoxamine—CYP1A2—Methoxsalen—hematologic cancer	0.00697	0.0113	CbGbCtD
Fluvoxamine—CYP3A5—Ifosfamide—hematologic cancer	0.00683	0.011	CbGbCtD
Fluvoxamine—CYP2E1—Mitoxantrone—hematologic cancer	0.00667	0.0108	CbGbCtD
Fluvoxamine—CYP1A2—Bortezomib—hematologic cancer	0.00663	0.0107	CbGbCtD
Fluvoxamine—CYP3A5—Imatinib—hematologic cancer	0.00653	0.0105	CbGbCtD
Fluvoxamine—CYP1A2—Daunorubicin—hematologic cancer	0.00634	0.0102	CbGbCtD
Fluvoxamine—CYP2D6—Hydroxyurea—hematologic cancer	0.00628	0.0101	CbGbCtD
Fluvoxamine—CYP2C19—Thalidomide—hematologic cancer	0.00626	0.0101	CbGbCtD
Fluvoxamine—CYP1A2—Alitretinoin—hematologic cancer	0.00621	0.01	CbGbCtD
Fluvoxamine—CYP2C9—Bortezomib—hematologic cancer	0.00598	0.00965	CbGbCtD
Fluvoxamine—CYP2C19—Teniposide—hematologic cancer	0.00597	0.00965	CbGbCtD
Fluvoxamine—CYP1A2—Thalidomide—hematologic cancer	0.00578	0.00933	CbGbCtD
Fluvoxamine—CYP3A4—Bexarotene—hematologic cancer	0.00567	0.00916	CbGbCtD
Fluvoxamine—ABCB1—Daunorubicin—hematologic cancer	0.00555	0.00896	CbGbCtD
Fluvoxamine—CYP2C19—Ifosfamide—hematologic cancer	0.00551	0.0089	CbGbCtD
Fluvoxamine—CYP2D6—Bortezomib—hematologic cancer	0.00546	0.00883	CbGbCtD
Fluvoxamine—CYP3A7—Irinotecan—hematologic cancer	0.00544	0.00878	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00544	0.00878	CbGbCtD
Fluvoxamine—ABCB1—Alitretinoin—hematologic cancer	0.00543	0.00878	CbGbCtD
Fluvoxamine—CYP3A4—Lomustine—hematologic cancer	0.00527	0.00851	CbGbCtD
Fluvoxamine—CYP3A4—Busulfan—hematologic cancer	0.00527	0.00851	CbGbCtD
Fluvoxamine—CYP2C19—Imatinib—hematologic cancer	0.00527	0.00851	CbGbCtD
Fluvoxamine—CYP3A5—Dasatinib—hematologic cancer	0.00524	0.00847	CbGbCtD
Fluvoxamine—CYP2C9—Thalidomide—hematologic cancer	0.00521	0.00841	CbGbCtD
Fluvoxamine—CYP2B6—Irinotecan—hematologic cancer	0.00518	0.00836	CbGbCtD
Fluvoxamine—CYP1A2—Dacarbazine—hematologic cancer	0.00497	0.00803	CbGbCtD
Fluvoxamine—CYP2C9—Teniposide—hematologic cancer	0.00497	0.00802	CbGbCtD
Fluvoxamine—CYP1A2—Imatinib—hematologic cancer	0.00486	0.00785	CbGbCtD
Fluvoxamine—CYP3A7—Vincristine—hematologic cancer	0.00475	0.00768	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00475	0.00768	CbGbCtD
Fluvoxamine—CYP3A4—Thiotepa—hematologic cancer	0.0047	0.00759	CbGbCtD
Fluvoxamine—CYP2C9—Ifosfamide—hematologic cancer	0.00458	0.0074	CbGbCtD
Fluvoxamine—CYP1A1—Dexamethasone—hematologic cancer	0.00447	0.00723	CbGbCtD
Fluvoxamine—CYP2C9—Imatinib—hematologic cancer	0.00438	0.00707	CbGbCtD
Fluvoxamine—ABCB1—Imatinib—hematologic cancer	0.00425	0.00686	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—hematologic cancer	0.00422	0.00682	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—hematologic cancer	0.0042	0.00679	CbGbCtD
Fluvoxamine—CYP3A5—Irinotecan—hematologic cancer	0.00408	0.00659	CbGbCtD
Fluvoxamine—CYP2D6—Imatinib—hematologic cancer	0.004	0.00647	CbGbCtD
Fluvoxamine—CYP2C9—Nilotinib—hematologic cancer	0.00398	0.00643	CbGbCtD
Fluvoxamine—CYP1A2—Dasatinib—hematologic cancer	0.0039	0.0063	CbGbCtD
Fluvoxamine—ABCB1—Nilotinib—hematologic cancer	0.00386	0.00624	CbGbCtD
Fluvoxamine—ABCB1—Vinorelbine—hematologic cancer	0.00383	0.00618	CbGbCtD
Fluvoxamine—CYP3A4—Methoxsalen—hematologic cancer	0.00365	0.0059	CbGbCtD
Fluvoxamine—CYP2D6—Nilotinib—hematologic cancer	0.00364	0.00588	CbGbCtD
Fluvoxamine—CYP2D6—Vinorelbine—hematologic cancer	0.00361	0.00583	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00358	0.00578	CbGbCtD
Fluvoxamine—CYP3A7—Dexamethasone—hematologic cancer	0.00358	0.00578	CbGbCtD
Fluvoxamine—CYP3A5—Vincristine—hematologic cancer	0.00356	0.00576	CbGbCtD
Fluvoxamine—CYP3A4—Bortezomib—hematologic cancer	0.00347	0.00561	CbGbCtD
Fluvoxamine—CYP2C19—Prednisone—hematologic cancer	0.00347	0.0056	CbGbCtD
Fluvoxamine—CYP2E1—Dexamethasone—hematologic cancer	0.00346	0.00558	CbGbCtD
Fluvoxamine—ABCB1—Dasatinib—hematologic cancer	0.00341	0.00551	CbGbCtD
Fluvoxamine—CYP2B6—Dexamethasone—hematologic cancer	0.00341	0.00551	CbGbCtD
Fluvoxamine—ABCB1—Mitoxantrone—hematologic cancer	0.00337	0.00545	CbGbCtD
Fluvoxamine—CYP3A4—Daunorubicin—hematologic cancer	0.00332	0.00537	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—hematologic cancer	0.00327	0.00528	CbGbCtD
Fluvoxamine—ABCB1—Betamethasone—hematologic cancer	0.003	0.00485	CbGbCtD
Fluvoxamine—ABCB1—Gemcitabine—hematologic cancer	0.00298	0.00481	CbGbCtD
Fluvoxamine—ABCB1—Prednisolone—hematologic cancer	0.00296	0.00479	CbGbCtD
Fluvoxamine—CYP3A4—Cytarabine—hematologic cancer	0.00293	0.00474	CbGbCtD
Fluvoxamine—CYP3A4—Teniposide—hematologic cancer	0.00289	0.00466	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—hematologic cancer	0.00283	0.00457	CbGbCtD
Fluvoxamine—ABCB1—Prednisone—hematologic cancer	0.0028	0.00452	CbGbCtD
Fluvoxamine—CYP3A5—Dexamethasone—hematologic cancer	0.00269	0.00434	CbGbCtD
Fluvoxamine—CYP3A4—Ifosfamide—hematologic cancer	0.00267	0.0043	CbGbCtD
Fluvoxamine—ABCB1—Irinotecan—hematologic cancer	0.00265	0.00429	CbGbCtD
Fluvoxamine—CYP3A4—Imatinib—hematologic cancer	0.00255	0.00411	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—hematologic cancer	0.00243	0.00393	CbGbCtD
Fluvoxamine—CYP3A4—Ruxolitinib—hematologic cancer	0.0024	0.00387	CbGbCtD
Fluvoxamine—ABCB1—Vinblastine—hematologic cancer	0.00236	0.00381	CbGbCtD
Fluvoxamine—ABCB1—Vincristine—hematologic cancer	0.00232	0.00375	CbGbCtD
Fluvoxamine—CYP3A4—Nilotinib—hematologic cancer	0.00231	0.00374	CbGbCtD
Fluvoxamine—CYP3A4—Vinorelbine—hematologic cancer	0.00229	0.00371	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—hematologic cancer	0.00223	0.0036	CbGbCtD
Fluvoxamine—CYP2D6—Vinblastine—hematologic cancer	0.00222	0.00359	CbGbCtD
Fluvoxamine—CYP2C19—Dexamethasone—hematologic cancer	0.00217	0.0035	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—hematologic cancer	0.00216	0.00349	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—hematologic cancer	0.00213	0.00343	CbGbCtD
Fluvoxamine—CYP3A4—Triamcinolone—hematologic cancer	0.0021	0.00339	CbGbCtD
Fluvoxamine—CYP3A4—Dasatinib—hematologic cancer	0.00204	0.0033	CbGbCtD
Fluvoxamine—CYP3A4—Mitoxantrone—hematologic cancer	0.00202	0.00326	CbGbCtD
Fluvoxamine—CYP2C9—Dexamethasone—hematologic cancer	0.0018	0.00291	CbGbCtD
Fluvoxamine—CYP3A4—Betamethasone—hematologic cancer	0.0018	0.00291	CbGbCtD
Fluvoxamine—CYP3A4—Prednisolone—hematologic cancer	0.00178	0.00287	CbGbCtD
Fluvoxamine—ABCB1—Dexamethasone—hematologic cancer	0.00175	0.00282	CbGbCtD
Fluvoxamine—CYP3A4—Prednisone—hematologic cancer	0.00168	0.00271	CbGbCtD
Fluvoxamine—CYP2D6—Dexamethasone—hematologic cancer	0.00165	0.00266	CbGbCtD
Fluvoxamine—CYP3A4—Irinotecan—hematologic cancer	0.00159	0.00257	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—hematologic cancer	0.00145	0.00234	CbGbCtD
Fluvoxamine—CYP3A4—Vinblastine—hematologic cancer	0.00141	0.00228	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—hematologic cancer	0.0014	0.00227	CbGbCtD
Fluvoxamine—CYP3A4—Vincristine—hematologic cancer	0.00139	0.00225	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—hematologic cancer	0.00137	0.00221	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—hematologic cancer	0.00127	0.00206	CbGbCtD
Fluvoxamine—CYP3A4—Dexamethasone—hematologic cancer	0.00105	0.00169	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—hematologic cancer	0.000869	0.0014	CbGbCtD
Fluvoxamine—SLC6A3—hematopoietic system—hematologic cancer	0.000734	0.0495	CbGeAlD
Fluvoxamine—SLC6A4—hematopoietic system—hematologic cancer	0.000673	0.0454	CbGeAlD
Fluvoxamine—CYP2C19—hematopoietic system—hematologic cancer	0.000557	0.0376	CbGeAlD
Fluvoxamine—CYP1A2—hematopoietic system—hematologic cancer	0.000455	0.0307	CbGeAlD
Fluvoxamine—CYP1A1—hematopoietic system—hematologic cancer	0.000449	0.0303	CbGeAlD
Fluvoxamine—SLC6A4—blood—hematologic cancer	0.000446	0.0301	CbGeAlD
Fluvoxamine—SIGMAR1—blood—hematologic cancer	0.000443	0.0299	CbGeAlD
Fluvoxamine—CYP3A5—hematopoietic system—hematologic cancer	0.000439	0.0296	CbGeAlD
Fluvoxamine—CYP2B6—hematopoietic system—hematologic cancer	0.000436	0.0294	CbGeAlD
Fluvoxamine—CYP2C9—hematopoietic system—hematologic cancer	0.000432	0.0291	CbGeAlD
Fluvoxamine—SIGMAR1—bone marrow—hematologic cancer	0.000428	0.0289	CbGeAlD
Fluvoxamine—SLC6A3—lung—hematologic cancer	0.000426	0.0288	CbGeAlD
Fluvoxamine—CYP2E1—hematopoietic system—hematologic cancer	0.00041	0.0276	CbGeAlD
Fluvoxamine—SLC6A3—testis—hematologic cancer	0.000402	0.0271	CbGeAlD
Fluvoxamine—SLC6A4—lung—hematologic cancer	0.000391	0.0263	CbGeAlD
Fluvoxamine—SIGMAR1—lung—hematologic cancer	0.000388	0.0262	CbGeAlD
Fluvoxamine—CYP2C19—blood—hematologic cancer	0.000369	0.0249	CbGeAlD
Fluvoxamine—SIGMAR1—testis—hematologic cancer	0.000366	0.0247	CbGeAlD
Fluvoxamine—CYP2B6—gonad—hematologic cancer	0.000332	0.0224	CbGeAlD
Fluvoxamine—CYP3A4—hematopoietic system—hematologic cancer	0.000329	0.0222	CbGeAlD
Fluvoxamine—CYP2D6—hematopoietic system—hematologic cancer	0.000324	0.0219	CbGeAlD
Fluvoxamine—CYP1A2—blood—hematologic cancer	0.000302	0.0203	CbGeAlD
Fluvoxamine—CYP1A1—blood—hematologic cancer	0.000297	0.0201	CbGeAlD
Fluvoxamine—CYP3A5—blood—hematologic cancer	0.000291	0.0196	CbGeAlD
Fluvoxamine—CYP2B6—blood—hematologic cancer	0.000289	0.0195	CbGeAlD
Fluvoxamine—CYP2C9—blood—hematologic cancer	0.000286	0.0193	CbGeAlD
Fluvoxamine—CYP2E1—blood—hematologic cancer	0.000271	0.0183	CbGeAlD
Fluvoxamine—SIGMAR1—lymph node—hematologic cancer	0.000265	0.0179	CbGeAlD
Fluvoxamine—CYP1A2—lung—hematologic cancer	0.000264	0.0178	CbGeAlD
Fluvoxamine—CYP1A1—lung—hematologic cancer	0.000261	0.0176	CbGeAlD
Fluvoxamine—CYP3A5—lung—hematologic cancer	0.000255	0.0172	CbGeAlD
Fluvoxamine—CYP2B6—lung—hematologic cancer	0.000253	0.0171	CbGeAlD
Fluvoxamine—CYP2B6—testis—hematologic cancer	0.000239	0.0161	CbGeAlD
Fluvoxamine—CYP2E1—lung—hematologic cancer	0.000238	0.016	CbGeAlD
Fluvoxamine—ABCB1—hematopoietic system—hematologic cancer	0.000233	0.0157	CbGeAlD
Fluvoxamine—CYP2E1—testis—hematologic cancer	0.000224	0.0151	CbGeAlD
Fluvoxamine—CYP3A4—blood—hematologic cancer	0.000218	0.0147	CbGeAlD
Fluvoxamine—CYP2D6—blood—hematologic cancer	0.000215	0.0145	CbGeAlD
Fluvoxamine—CYP1A1—lymph node—hematologic cancer	0.000178	0.012	CbGeAlD
Fluvoxamine—CYP2D6—testis—hematologic cancer	0.000178	0.012	CbGeAlD
Fluvoxamine—ABCB1—gonad—hematologic cancer	0.000177	0.012	CbGeAlD
Fluvoxamine—ABCB1—blood—hematologic cancer	0.000155	0.0104	CbGeAlD
Fluvoxamine—ABCB1—bone marrow—hematologic cancer	0.00015	0.0101	CbGeAlD
Fluvoxamine—ABCB1—lung—hematologic cancer	0.000135	0.00914	CbGeAlD
Fluvoxamine—ABCB1—testis—hematologic cancer	0.000128	0.00862	CbGeAlD
Fluvoxamine—ABCB1—lymph node—hematologic cancer	9.26e-05	0.00625	CbGeAlD
Fluvoxamine—Diarrhoea—Etoposide—hematologic cancer	1.18e-05	4.69e-05	CcSEcCtD
Fluvoxamine—Anorexia—Prednisone—hematologic cancer	1.18e-05	4.68e-05	CcSEcCtD
Fluvoxamine—Eye disorder—Doxorubicin—hematologic cancer	1.18e-05	4.68e-05	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—hematologic cancer	1.17e-05	4.67e-05	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—hematologic cancer	1.17e-05	4.67e-05	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—hematologic cancer	1.17e-05	4.65e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Betamethasone—hematologic cancer	1.17e-05	4.65e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Dexamethasone—hematologic cancer	1.17e-05	4.65e-05	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—hematologic cancer	1.17e-05	4.64e-05	CcSEcCtD
Fluvoxamine—Flatulence—Epirubicin—hematologic cancer	1.17e-05	4.64e-05	CcSEcCtD
Fluvoxamine—Tension—Epirubicin—hematologic cancer	1.16e-05	4.62e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.16e-05	4.61e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Betamethasone—hematologic cancer	1.16e-05	4.61e-05	CcSEcCtD
Fluvoxamine—Dysgeusia—Epirubicin—hematologic cancer	1.16e-05	4.61e-05	CcSEcCtD
Fluvoxamine—Hypersensitivity—Triamcinolone—hematologic cancer	1.15e-05	4.58e-05	CcSEcCtD
Fluvoxamine—Nervousness—Epirubicin—hematologic cancer	1.15e-05	4.57e-05	CcSEcCtD
Fluvoxamine—Back pain—Epirubicin—hematologic cancer	1.15e-05	4.55e-05	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—hematologic cancer	1.14e-05	4.54e-05	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—hematologic cancer	1.14e-05	4.54e-05	CcSEcCtD
Fluvoxamine—Dizziness—Etoposide—hematologic cancer	1.14e-05	4.53e-05	CcSEcCtD
Fluvoxamine—Muscle spasms—Epirubicin—hematologic cancer	1.14e-05	4.53e-05	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—hematologic cancer	1.14e-05	4.52e-05	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—hematologic cancer	1.13e-05	4.5e-05	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—hematologic cancer	1.13e-05	4.49e-05	CcSEcCtD
Fluvoxamine—Urticaria—Dexamethasone—hematologic cancer	1.13e-05	4.48e-05	CcSEcCtD
Fluvoxamine—Urticaria—Betamethasone—hematologic cancer	1.13e-05	4.48e-05	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.13e-05	4.48e-05	CcSEcCtD
Fluvoxamine—Dizziness—Prednisolone—hematologic cancer	1.13e-05	4.47e-05	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—hematologic cancer	1.13e-05	4.47e-05	CcSEcCtD
Fluvoxamine—Asthenia—Triamcinolone—hematologic cancer	1.12e-05	4.46e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Dexamethasone—hematologic cancer	1.12e-05	4.46e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Betamethasone—hematologic cancer	1.12e-05	4.46e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Dexamethasone—hematologic cancer	1.12e-05	4.46e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Betamethasone—hematologic cancer	1.12e-05	4.46e-05	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—hematologic cancer	1.12e-05	4.44e-05	CcSEcCtD
Fluvoxamine—Insomnia—Prednisone—hematologic cancer	1.12e-05	4.44e-05	CcSEcCtD
Fluvoxamine—Vision blurred—Epirubicin—hematologic cancer	1.12e-05	4.44e-05	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—hematologic cancer	1.11e-05	4.42e-05	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisone—hematologic cancer	1.11e-05	4.41e-05	CcSEcCtD
Fluvoxamine—Pruritus—Triamcinolone—hematologic cancer	1.11e-05	4.4e-05	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—hematologic cancer	1.1e-05	4.39e-05	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—hematologic cancer	1.1e-05	4.38e-05	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Epirubicin—hematologic cancer	1.1e-05	4.37e-05	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—hematologic cancer	1.1e-05	4.36e-05	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—hematologic cancer	1.1e-05	4.36e-05	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—hematologic cancer	1.1e-05	4.36e-05	CcSEcCtD
Fluvoxamine—Anaemia—Epirubicin—hematologic cancer	1.1e-05	4.35e-05	CcSEcCtD
Fluvoxamine—Agitation—Epirubicin—hematologic cancer	1.09e-05	4.33e-05	CcSEcCtD
Fluvoxamine—Dyspepsia—Prednisone—hematologic cancer	1.09e-05	4.32e-05	CcSEcCtD
Fluvoxamine—Rash—Etoposide—hematologic cancer	1.09e-05	4.32e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—hematologic cancer	1.09e-05	4.32e-05	CcSEcCtD
Fluvoxamine—Headache—Etoposide—hematologic cancer	1.08e-05	4.29e-05	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—hematologic cancer	1.08e-05	4.29e-05	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—hematologic cancer	1.08e-05	4.28e-05	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—hematologic cancer	1.08e-05	4.28e-05	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—hematologic cancer	1.08e-05	4.28e-05	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—hematologic cancer	1.08e-05	4.27e-05	CcSEcCtD
Fluvoxamine—Decreased appetite—Prednisone—hematologic cancer	1.07e-05	4.27e-05	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—hematologic cancer	1.07e-05	4.27e-05	CcSEcCtD
Fluvoxamine—Rash—Prednisolone—hematologic cancer	1.07e-05	4.26e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisolone—hematologic cancer	1.07e-05	4.26e-05	CcSEcCtD
Fluvoxamine—Malaise—Epirubicin—hematologic cancer	1.07e-05	4.25e-05	CcSEcCtD
Fluvoxamine—Fatigue—Prednisone—hematologic cancer	1.07e-05	4.24e-05	CcSEcCtD
Fluvoxamine—Headache—Prednisolone—hematologic cancer	1.07e-05	4.24e-05	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—hematologic cancer	1.06e-05	4.23e-05	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—hematologic cancer	1.06e-05	4.23e-05	CcSEcCtD
Fluvoxamine—Vertigo—Epirubicin—hematologic cancer	1.06e-05	4.23e-05	CcSEcCtD
Fluvoxamine—Syncope—Epirubicin—hematologic cancer	1.06e-05	4.22e-05	CcSEcCtD
Fluvoxamine—Leukopenia—Epirubicin—hematologic cancer	1.06e-05	4.21e-05	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—hematologic cancer	1.06e-05	4.21e-05	CcSEcCtD
Fluvoxamine—Constipation—Prednisone—hematologic cancer	1.06e-05	4.2e-05	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—hematologic cancer	1.05e-05	4.19e-05	CcSEcCtD
Fluvoxamine—Palpitations—Epirubicin—hematologic cancer	1.05e-05	4.16e-05	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—hematologic cancer	1.04e-05	4.14e-05	CcSEcCtD
Fluvoxamine—Loss of consciousness—Epirubicin—hematologic cancer	1.04e-05	4.14e-05	CcSEcCtD
Fluvoxamine—Dizziness—Triamcinolone—hematologic cancer	1.03e-05	4.11e-05	CcSEcCtD
Fluvoxamine—Cough—Epirubicin—hematologic cancer	1.03e-05	4.11e-05	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—hematologic cancer	1.03e-05	4.11e-05	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—hematologic cancer	1.03e-05	4.11e-05	CcSEcCtD
Fluvoxamine—Convulsion—Epirubicin—hematologic cancer	1.03e-05	4.08e-05	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—hematologic cancer	1.03e-05	4.08e-05	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—hematologic cancer	1.02e-05	4.07e-05	CcSEcCtD
Fluvoxamine—Hypertension—Epirubicin—hematologic cancer	1.02e-05	4.06e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisone—hematologic cancer	1.02e-05	4.05e-05	CcSEcCtD
Fluvoxamine—Asthenia—Betamethasone—hematologic cancer	1.02e-05	4.05e-05	CcSEcCtD
Fluvoxamine—Asthenia—Dexamethasone—hematologic cancer	1.02e-05	4.05e-05	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—hematologic cancer	1.02e-05	4.04e-05	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—hematologic cancer	1.01e-05	4.03e-05	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—hematologic cancer	1.01e-05	4.03e-05	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—hematologic cancer	1.01e-05	4.02e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Prednisone—hematologic cancer	1.01e-05	4.02e-05	CcSEcCtD
Fluvoxamine—Nausea—Prednisolone—hematologic cancer	1.01e-05	4.02e-05	CcSEcCtD
Fluvoxamine—Chest pain—Epirubicin—hematologic cancer	1.01e-05	4.01e-05	CcSEcCtD
Fluvoxamine—Myalgia—Epirubicin—hematologic cancer	1.01e-05	4.01e-05	CcSEcCtD
Fluvoxamine—Arthralgia—Epirubicin—hematologic cancer	1.01e-05	4.01e-05	CcSEcCtD
Fluvoxamine—Agitation—Doxorubicin—hematologic cancer	1.01e-05	4e-05	CcSEcCtD
Fluvoxamine—Anxiety—Epirubicin—hematologic cancer	1.01e-05	3.99e-05	CcSEcCtD
Fluvoxamine—Pruritus—Dexamethasone—hematologic cancer	1e-05	3.99e-05	CcSEcCtD
Fluvoxamine—Pruritus—Betamethasone—hematologic cancer	1e-05	3.99e-05	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—hematologic cancer	9.99e-06	3.97e-05	CcSEcCtD
Fluvoxamine—Discomfort—Epirubicin—hematologic cancer	9.97e-06	3.96e-05	CcSEcCtD
Fluvoxamine—Vomiting—Triamcinolone—hematologic cancer	9.95e-06	3.95e-05	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—hematologic cancer	9.89e-06	3.93e-05	CcSEcCtD
Fluvoxamine—Rash—Triamcinolone—hematologic cancer	9.87e-06	3.92e-05	CcSEcCtD
Fluvoxamine—Dry mouth—Epirubicin—hematologic cancer	9.87e-06	3.92e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Triamcinolone—hematologic cancer	9.86e-06	3.92e-05	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—hematologic cancer	9.85e-06	3.91e-05	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—hematologic cancer	9.85e-06	3.91e-05	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—hematologic cancer	9.83e-06	3.91e-05	CcSEcCtD
Fluvoxamine—Urticaria—Prednisone—hematologic cancer	9.82e-06	3.9e-05	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—hematologic cancer	9.81e-06	3.9e-05	CcSEcCtD
Fluvoxamine—Headache—Triamcinolone—hematologic cancer	9.8e-06	3.89e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Prednisone—hematologic cancer	9.77e-06	3.88e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Prednisone—hematologic cancer	9.77e-06	3.88e-05	CcSEcCtD
Fluvoxamine—Confusional state—Epirubicin—hematologic cancer	9.75e-06	3.87e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Dexamethasone—hematologic cancer	9.71e-06	3.86e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Betamethasone—hematologic cancer	9.71e-06	3.86e-05	CcSEcCtD
Fluvoxamine—Palpitations—Doxorubicin—hematologic cancer	9.69e-06	3.85e-05	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Epirubicin—hematologic cancer	9.67e-06	3.84e-05	CcSEcCtD
Fluvoxamine—Oedema—Epirubicin—hematologic cancer	9.67e-06	3.84e-05	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—hematologic cancer	9.66e-06	3.84e-05	CcSEcCtD
Fluvoxamine—Loss of consciousness—Doxorubicin—hematologic cancer	9.64e-06	3.83e-05	CcSEcCtD
Fluvoxamine—Infection—Epirubicin—hematologic cancer	9.61e-06	3.82e-05	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—hematologic cancer	9.57e-06	3.8e-05	CcSEcCtD
Fluvoxamine—Shock—Epirubicin—hematologic cancer	9.51e-06	3.78e-05	CcSEcCtD
Fluvoxamine—Convulsion—Doxorubicin—hematologic cancer	9.5e-06	3.77e-05	CcSEcCtD
Fluvoxamine—Nervous system disorder—Epirubicin—hematologic cancer	9.48e-06	3.77e-05	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Epirubicin—hematologic cancer	9.47e-06	3.76e-05	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—hematologic cancer	9.46e-06	3.76e-05	CcSEcCtD
Fluvoxamine—Tachycardia—Epirubicin—hematologic cancer	9.44e-06	3.75e-05	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	9.41e-06	3.74e-05	CcSEcCtD
Fluvoxamine—Dizziness—Dexamethasone—hematologic cancer	9.39e-06	3.73e-05	CcSEcCtD
Fluvoxamine—Dizziness—Betamethasone—hematologic cancer	9.39e-06	3.73e-05	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Epirubicin—hematologic cancer	9.35e-06	3.71e-05	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—hematologic cancer	9.35e-06	3.71e-05	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—hematologic cancer	9.33e-06	3.71e-05	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—hematologic cancer	9.33e-06	3.71e-05	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—hematologic cancer	9.33e-06	3.71e-05	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—hematologic cancer	9.3e-06	3.7e-05	CcSEcCtD
Fluvoxamine—Nausea—Triamcinolone—hematologic cancer	9.29e-06	3.69e-05	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—hematologic cancer	9.28e-06	3.69e-05	CcSEcCtD
Fluvoxamine—Discomfort—Doxorubicin—hematologic cancer	9.22e-06	3.66e-05	CcSEcCtD
Fluvoxamine—Anorexia—Epirubicin—hematologic cancer	9.22e-06	3.66e-05	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—hematologic cancer	9.21e-06	3.66e-05	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—hematologic cancer	9.19e-06	3.65e-05	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—hematologic cancer	9.13e-06	3.63e-05	CcSEcCtD
Fluvoxamine—Hypersensitivity—Prednisone—hematologic cancer	9.11e-06	3.62e-05	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—hematologic cancer	9.1e-06	3.61e-05	CcSEcCtD
Fluvoxamine—Hypotension—Epirubicin—hematologic cancer	9.04e-06	3.59e-05	CcSEcCtD
Fluvoxamine—Vomiting—Dexamethasone—hematologic cancer	9.03e-06	3.59e-05	CcSEcCtD
Fluvoxamine—Vomiting—Betamethasone—hematologic cancer	9.03e-06	3.59e-05	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—hematologic cancer	9.02e-06	3.58e-05	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—hematologic cancer	8.98e-06	3.57e-05	CcSEcCtD
Fluvoxamine—Rash—Betamethasone—hematologic cancer	8.95e-06	3.56e-05	CcSEcCtD
Fluvoxamine—Rash—Dexamethasone—hematologic cancer	8.95e-06	3.56e-05	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—hematologic cancer	8.95e-06	3.56e-05	CcSEcCtD
Fluvoxamine—Oedema—Doxorubicin—hematologic cancer	8.95e-06	3.56e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Dexamethasone—hematologic cancer	8.94e-06	3.55e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Betamethasone—hematologic cancer	8.94e-06	3.55e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	8.92e-06	3.54e-05	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—hematologic cancer	8.91e-06	3.54e-05	CcSEcCtD
Fluvoxamine—Headache—Betamethasone—hematologic cancer	8.89e-06	3.53e-05	CcSEcCtD
Fluvoxamine—Headache—Dexamethasone—hematologic cancer	8.89e-06	3.53e-05	CcSEcCtD
Fluvoxamine—Infection—Doxorubicin—hematologic cancer	8.89e-06	3.53e-05	CcSEcCtD
Fluvoxamine—Asthenia—Prednisone—hematologic cancer	8.87e-06	3.52e-05	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—hematologic cancer	8.84e-06	3.51e-05	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.81e-06	3.5e-05	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—hematologic cancer	8.8e-06	3.5e-05	CcSEcCtD
Fluvoxamine—Nervous system disorder—Doxorubicin—hematologic cancer	8.77e-06	3.49e-05	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Doxorubicin—hematologic cancer	8.76e-06	3.48e-05	CcSEcCtD
Fluvoxamine—Pruritus—Prednisone—hematologic cancer	8.75e-06	3.48e-05	CcSEcCtD
Fluvoxamine—Insomnia—Epirubicin—hematologic cancer	8.75e-06	3.48e-05	CcSEcCtD
Fluvoxamine—Tachycardia—Doxorubicin—hematologic cancer	8.73e-06	3.47e-05	CcSEcCtD
Fluvoxamine—Paraesthesia—Epirubicin—hematologic cancer	8.68e-06	3.45e-05	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Doxorubicin—hematologic cancer	8.65e-06	3.44e-05	CcSEcCtD
Fluvoxamine—Dyspnoea—Epirubicin—hematologic cancer	8.62e-06	3.43e-05	CcSEcCtD
Fluvoxamine—Somnolence—Epirubicin—hematologic cancer	8.6e-06	3.42e-05	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—hematologic cancer	8.53e-06	3.39e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—hematologic cancer	8.51e-06	3.38e-05	CcSEcCtD
Fluvoxamine—Dyspepsia—Epirubicin—hematologic cancer	8.51e-06	3.38e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Prednisone—hematologic cancer	8.46e-06	3.36e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—hematologic cancer	8.45e-06	3.36e-05	CcSEcCtD
Fluvoxamine—Nausea—Betamethasone—hematologic cancer	8.43e-06	3.35e-05	CcSEcCtD
Fluvoxamine—Nausea—Dexamethasone—hematologic cancer	8.43e-06	3.35e-05	CcSEcCtD
Fluvoxamine—Decreased appetite—Epirubicin—hematologic cancer	8.41e-06	3.34e-05	CcSEcCtD
Fluvoxamine—Hypotension—Doxorubicin—hematologic cancer	8.36e-06	3.32e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.35e-06	3.32e-05	CcSEcCtD
Fluvoxamine—Fatigue—Epirubicin—hematologic cancer	8.34e-06	3.31e-05	CcSEcCtD
Fluvoxamine—Constipation—Epirubicin—hematologic cancer	8.27e-06	3.29e-05	CcSEcCtD
Fluvoxamine—Pain—Epirubicin—hematologic cancer	8.27e-06	3.29e-05	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—hematologic cancer	8.21e-06	3.26e-05	CcSEcCtD
Fluvoxamine—Dizziness—Prednisone—hematologic cancer	8.18e-06	3.25e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—hematologic cancer	8.17e-06	3.25e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—hematologic cancer	8.17e-06	3.25e-05	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.15e-06	3.24e-05	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—hematologic cancer	8.09e-06	3.22e-05	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—hematologic cancer	8.03e-06	3.19e-05	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—hematologic cancer	7.98e-06	3.17e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Epirubicin—hematologic cancer	7.97e-06	3.17e-05	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—hematologic cancer	7.95e-06	3.16e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Epirubicin—hematologic cancer	7.91e-06	3.14e-05	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—hematologic cancer	7.88e-06	3.13e-05	CcSEcCtD
Fluvoxamine—Vomiting—Prednisone—hematologic cancer	7.86e-06	3.12e-05	CcSEcCtD
Fluvoxamine—Rash—Prednisone—hematologic cancer	7.8e-06	3.1e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisone—hematologic cancer	7.79e-06	3.09e-05	CcSEcCtD
Fluvoxamine—Decreased appetite—Doxorubicin—hematologic cancer	7.78e-06	3.09e-05	CcSEcCtD
Fluvoxamine—Headache—Prednisone—hematologic cancer	7.75e-06	3.08e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	7.72e-06	3.07e-05	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—hematologic cancer	7.71e-06	3.07e-05	CcSEcCtD
Fluvoxamine—Urticaria—Epirubicin—hematologic cancer	7.68e-06	3.05e-05	CcSEcCtD
Fluvoxamine—Pain—Doxorubicin—hematologic cancer	7.65e-06	3.04e-05	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—hematologic cancer	7.65e-06	3.04e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Epirubicin—hematologic cancer	7.64e-06	3.04e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Epirubicin—hematologic cancer	7.64e-06	3.04e-05	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—hematologic cancer	7.61e-06	3.02e-05	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—hematologic cancer	7.41e-06	2.95e-05	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—hematologic cancer	7.37e-06	2.93e-05	CcSEcCtD
Fluvoxamine—Nausea—Prednisone—hematologic cancer	7.34e-06	2.92e-05	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.32e-06	2.91e-05	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—hematologic cancer	7.31e-06	2.9e-05	CcSEcCtD
Fluvoxamine—Hypersensitivity—Epirubicin—hematologic cancer	7.12e-06	2.83e-05	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—hematologic cancer	7.11e-06	2.82e-05	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—hematologic cancer	7.07e-06	2.81e-05	CcSEcCtD
Fluvoxamine—Body temperature increased—Doxorubicin—hematologic cancer	7.07e-06	2.81e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—hematologic cancer	7.07e-06	2.81e-05	CcSEcCtD
Fluvoxamine—Asthenia—Epirubicin—hematologic cancer	6.94e-06	2.76e-05	CcSEcCtD
Fluvoxamine—Pruritus—Epirubicin—hematologic cancer	6.84e-06	2.72e-05	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—hematologic cancer	6.83e-06	2.72e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Epirubicin—hematologic cancer	6.62e-06	2.63e-05	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—hematologic cancer	6.59e-06	2.62e-05	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—hematologic cancer	6.57e-06	2.61e-05	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—hematologic cancer	6.51e-06	2.59e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—hematologic cancer	6.51e-06	2.59e-05	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—hematologic cancer	6.47e-06	2.57e-05	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—hematologic cancer	6.42e-06	2.55e-05	CcSEcCtD
Fluvoxamine—Dizziness—Epirubicin—hematologic cancer	6.39e-06	2.54e-05	CcSEcCtD
Fluvoxamine—Pruritus—Doxorubicin—hematologic cancer	6.33e-06	2.52e-05	CcSEcCtD
Fluvoxamine—Vomiting—Epirubicin—hematologic cancer	6.15e-06	2.44e-05	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—hematologic cancer	6.14e-06	2.44e-05	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—hematologic cancer	6.12e-06	2.43e-05	CcSEcCtD
Fluvoxamine—Rash—Epirubicin—hematologic cancer	6.1e-06	2.42e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Epirubicin—hematologic cancer	6.09e-06	2.42e-05	CcSEcCtD
Fluvoxamine—Headache—Epirubicin—hematologic cancer	6.06e-06	2.41e-05	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—hematologic cancer	5.92e-06	2.35e-05	CcSEcCtD
Fluvoxamine—Nausea—Epirubicin—hematologic cancer	5.74e-06	2.28e-05	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—hematologic cancer	5.69e-06	2.26e-05	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—hematologic cancer	5.64e-06	2.24e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—hematologic cancer	5.64e-06	2.24e-05	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—hematologic cancer	5.61e-06	2.23e-05	CcSEcCtD
Fluvoxamine—Nausea—Doxorubicin—hematologic cancer	5.31e-06	2.11e-05	CcSEcCtD
Fluvoxamine—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.91e-06	7.8e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CRABP1—hematologic cancer	3.9e-06	7.79e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SLC22A1—hematologic cancer	3.9e-06	7.79e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—hematologic cancer	3.9e-06	7.78e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.88e-06	7.75e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—IDH2—hematologic cancer	3.87e-06	7.73e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HMMR—hematologic cancer	3.87e-06	7.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.87e-06	7.73e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SDC1—hematologic cancer	3.82e-06	7.62e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—hematologic cancer	3.82e-06	7.62e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.81e-06	7.61e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—hematologic cancer	3.81e-06	7.6e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALOX5—hematologic cancer	3.8e-06	7.59e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SDC1—hematologic cancer	3.79e-06	7.56e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.74e-06	7.48e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ABCB1—hematologic cancer	3.69e-06	7.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NUP98—hematologic cancer	3.68e-06	7.36e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.65e-06	7.29e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.64e-06	7.27e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.63e-06	7.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.62e-06	7.22e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ABCB1—hematologic cancer	3.61e-06	7.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ABCB1—hematologic cancer	3.6e-06	7.2e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—hematologic cancer	3.6e-06	7.18e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CG—hematologic cancer	3.59e-06	7.18e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTM1—hematologic cancer	3.58e-06	7.15e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NCOR1—hematologic cancer	3.58e-06	7.15e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADCY7—hematologic cancer	3.58e-06	7.14e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NCOA3—hematologic cancer	3.58e-06	7.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.57e-06	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NUP214—hematologic cancer	3.55e-06	7.09e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ACP5—hematologic cancer	3.54e-06	7.07e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CA9—hematologic cancer	3.54e-06	7.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CD44—hematologic cancer	3.53e-06	7.05e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NQO1—hematologic cancer	3.53e-06	7.05e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.51e-06	7.02e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTM1—hematologic cancer	3.51e-06	7e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NCOR1—hematologic cancer	3.51e-06	7e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTM1—hematologic cancer	3.5e-06	6.99e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NCOR1—hematologic cancer	3.5e-06	6.99e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.5e-06	6.98e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.48e-06	6.95e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ABCG2—hematologic cancer	3.48e-06	6.95e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—MTR—hematologic cancer	3.48e-06	6.95e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.46e-06	6.9e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CD44—hematologic cancer	3.45e-06	6.88e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NQO1—hematologic cancer	3.45e-06	6.88e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.41e-06	6.82e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO2—hematologic cancer	3.41e-06	6.81e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ABCB1—hematologic cancer	3.41e-06	6.8e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYCS—hematologic cancer	3.34e-06	6.67e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CREBBP—hematologic cancer	3.33e-06	6.65e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—IDH1—hematologic cancer	3.33e-06	6.65e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	3.32e-06	6.63e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—hematologic cancer	3.31e-06	6.61e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTM1—hematologic cancer	3.31e-06	6.6e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NCOR1—hematologic cancer	3.31e-06	6.6e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TXN—hematologic cancer	3.29e-06	6.58e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.29e-06	6.58e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.29e-06	6.58e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYCS—hematologic cancer	3.26e-06	6.51e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.26e-06	6.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NQO1—hematologic cancer	3.25e-06	6.48e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CD44—hematologic cancer	3.25e-06	6.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.24e-06	6.47e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SDC1—hematologic cancer	3.23e-06	6.46e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.22e-06	6.44e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CD44—hematologic cancer	3.22e-06	6.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NQO1—hematologic cancer	3.22e-06	6.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—MTHFR—hematologic cancer	3.16e-06	6.32e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CD—hematologic cancer	3.16e-06	6.31e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.15e-06	6.29e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ALB—hematologic cancer	3.12e-06	6.23e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—MTHFR—hematologic cancer	3.1e-06	6.19e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.1e-06	6.18e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—MTHFR—hematologic cancer	3.09e-06	6.17e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.09e-06	6.17e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYCS—hematologic cancer	3.07e-06	6.13e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.05e-06	6.09e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYCS—hematologic cancer	3.05e-06	6.08e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	3.03e-06	6.04e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.01e-06	6.01e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.01e-06	6.01e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.99e-06	5.96e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3R1—hematologic cancer	2.98e-06	5.96e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.94e-06	5.88e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.94e-06	5.86e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—MTHFR—hematologic cancer	2.92e-06	5.83e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.92e-06	5.82e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—hematologic cancer	2.87e-06	5.74e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.85e-06	5.69e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NUP98—hematologic cancer	2.84e-06	5.68e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.79e-06	5.56e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.76e-06	5.51e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.76e-06	5.51e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CB—hematologic cancer	2.75e-06	5.5e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CD44—hematologic cancer	2.75e-06	5.49e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NQO1—hematologic cancer	2.75e-06	5.49e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NUP214—hematologic cancer	2.74e-06	5.47e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.72e-06	5.44e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.71e-06	5.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.71e-06	5.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.71e-06	5.4e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.69e-06	5.38e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—MTR—hematologic cancer	2.69e-06	5.36e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.69e-06	5.36e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.68e-06	5.36e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CG—hematologic cancer	2.66e-06	5.31e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NCOR1—hematologic cancer	2.64e-06	5.27e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTM1—hematologic cancer	2.64e-06	5.27e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO2—hematologic cancer	2.63e-06	5.26e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CG—hematologic cancer	2.6e-06	5.2e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYCS—hematologic cancer	2.6e-06	5.2e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.6e-06	5.19e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.6e-06	5.18e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.59e-06	5.16e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.57e-06	5.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.56e-06	5.12e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.55e-06	5.1e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.54e-06	5.07e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.5e-06	4.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.49e-06	4.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.49e-06	4.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.47e-06	4.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.47e-06	4.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CREBBP—hematologic cancer	2.46e-06	4.92e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CG—hematologic cancer	2.45e-06	4.9e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CREBBP—hematologic cancer	2.41e-06	4.82e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.41e-06	4.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.39e-06	4.77e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTEN—hematologic cancer	2.38e-06	4.75e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.34e-06	4.67e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.33e-06	4.66e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.33e-06	4.65e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ALB—hematologic cancer	2.31e-06	4.61e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.29e-06	4.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CD—hematologic cancer	2.29e-06	4.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.28e-06	4.56e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CREBBP—hematologic cancer	2.28e-06	4.54e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—EP300—hematologic cancer	2.27e-06	4.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALB—hematologic cancer	2.26e-06	4.51e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALB—hematologic cancer	2.26e-06	4.5e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.22e-06	4.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.21e-06	4.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.2e-06	4.39e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.18e-06	4.35e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.17e-06	4.33e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3R1—hematologic cancer	2.16e-06	4.31e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CD—hematologic cancer	2.16e-06	4.31e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3R1—hematologic cancer	2.16e-06	4.31e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALB—hematologic cancer	2.13e-06	4.25e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CD44—hematologic cancer	2.12e-06	4.24e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.12e-06	4.24e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.11e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.11e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.11e-06	4.21e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3R1—hematologic cancer	2.04e-06	4.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CB—hematologic cancer	2.04e-06	4.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.01e-06	4.01e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYCS—hematologic cancer	2.01e-06	4.01e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2e-06	3.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CB—hematologic cancer	2e-06	3.98e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.99e-06	3.97e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.96e-06	3.91e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.92e-06	3.84e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.88e-06	3.76e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.86e-06	3.72e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.86e-06	3.72e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.85e-06	3.69e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.83e-06	3.66e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.82e-06	3.63e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.77e-06	3.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.77e-06	3.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTEN—hematologic cancer	1.76e-06	3.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALB—hematologic cancer	1.74e-06	3.48e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTEN—hematologic cancer	1.72e-06	3.44e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.72e-06	3.44e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTEN—hematologic cancer	1.72e-06	3.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.71e-06	3.42e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALB—hematologic cancer	1.7e-06	3.4e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.7e-06	3.39e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.68e-06	3.35e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—EP300—hematologic cancer	1.68e-06	3.35e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.68e-06	3.35e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.67e-06	3.33e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—EP300—hematologic cancer	1.64e-06	3.28e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.64e-06	3.28e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—EP300—hematologic cancer	1.64e-06	3.28e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.63e-06	3.25e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.63e-06	3.25e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.63e-06	3.25e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTEN—hematologic cancer	1.63e-06	3.24e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.62e-06	3.24e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.61e-06	3.21e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALB—hematologic cancer	1.6e-06	3.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALB—hematologic cancer	1.59e-06	3.17e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.57e-06	3.12e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—EP300—hematologic cancer	1.55e-06	3.09e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.54e-06	3.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.53e-06	3.06e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.52e-06	3.04e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.5e-06	3e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.45e-06	2.9e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.44e-06	2.87e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.42e-06	2.83e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.4e-06	2.8e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.38e-06	2.75e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—AKT1—hematologic cancer	1.37e-06	2.74e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALB—hematologic cancer	1.36e-06	2.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTEN—hematologic cancer	1.33e-06	2.66e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.3e-06	2.59e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTEN—hematologic cancer	1.3e-06	2.59e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—EP300—hematologic cancer	1.27e-06	2.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.24e-06	2.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—EP300—hematologic cancer	1.24e-06	2.47e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.22e-06	2.44e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.22e-06	2.43e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.21e-06	2.42e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTEN—hematologic cancer	1.21e-06	2.42e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.21e-06	2.41e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.2e-06	2.39e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—EP300—hematologic cancer	1.17e-06	2.33e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—EP300—hematologic cancer	1.16e-06	2.31e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CA—hematologic cancer	1.15e-06	2.29e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.12e-06	2.24e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.06e-06	2.12e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALB—hematologic cancer	1.05e-06	2.09e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTEN—hematologic cancer	1.04e-06	2.07e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—AKT1—hematologic cancer	1.01e-06	2.03e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1e-06	2e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—AKT1—hematologic cancer	9.94e-07	1.98e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—AKT1—hematologic cancer	9.92e-07	1.98e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—EP300—hematologic cancer	9.88e-07	1.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	9.38e-07	1.87e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—AKT1—hematologic cancer	9.37e-07	1.87e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	9.26e-07	1.85e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CA—hematologic cancer	9.16e-07	1.83e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.63e-07	1.72e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	8.56e-07	1.71e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTEN—hematologic cancer	8e-07	1.6e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—AKT1—hematologic cancer	7.67e-07	1.53e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—EP300—hematologic cancer	7.63e-07	1.52e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—AKT1—hematologic cancer	7.48e-07	1.49e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	7.31e-07	1.46e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—AKT1—hematologic cancer	7.05e-07	1.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—AKT1—hematologic cancer	6.99e-07	1.4e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—AKT1—hematologic cancer	5.97e-07	1.19e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.64e-07	1.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—AKT1—hematologic cancer	4.61e-07	9.2e-06	CbGpPWpGaD
